ALLR

Allarity Therapeutics (ALLR)

Allarity Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ALLR

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/19	05:05	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/09/17	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/09/16	21:00	GlobeNewswire Inc.	Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/09/13	21:53	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/09/13	21:45	GlobeNewswire Inc.	Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/09/11	21:00	GlobeNewswire Inc.	Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/09/10	22:15	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/09/10	05:05	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/09/09	22:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/08/31	05:05	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/08/30	06:57	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/08/22	05:55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/08/06	06:24	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/07/26	22:00	GlobeNewswire Inc.	Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/07/26	19:04	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/07/24	19:00	GlobeNewswire Inc.	Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/07/24	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/07/22	19:30	GlobeNewswire Inc.	Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/07/22	19:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/06/27	21:00	GlobeNewswire Inc.	Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/06/25	21:00	GlobeNewswire Inc.	Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/06/06	21:54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/05/24	21:55	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/05/21	21:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/05/20	21:00	GlobeNewswire Inc.	Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/05/18	05:08	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/05/15	22:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/05/15	05:45	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/05/15	05:01	GlobeNewswire Inc.	Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances	NASDAQ:ALLR	Allarity Therapeutics Inc
2024/05/10	00:21	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ALLR	Allarity Therapeutics Inc